Clinical trial
A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With…
NCT00112060 · Spectrum Pharmaceuticals, Inc, Industry · Withdrawn
Key facts
| NCT number | NCT00112060 |
|---|---|
| Title | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | PT-523 for Injection |
| Enrollment | 0 |
| Start date | Apr 1, 2008 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | May 30, 2005 |
| Last update posted | Mar 31, 2014 |
| Countries | Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: